JNJ — Johnson & Johnson

Johnson & Johnson Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Worldwide Sales: $24.1 billion, reflecting a 6.4% operational growth despite a 540 basis point headwind from STELARA.
• Net Earnings: $5.2 billion; diluted EPS at $2.14, down from $4.54 YoY.
• Adjusted Net Earnings: $6.6 billion; adjusted diluted EPS at $2.70, a decrease of 1.4% YoY.
• Innovative Medicine Sales: $15.4 billion, up 7.4% operationally, with significant contributions from oncology and immunology.
• MedTech Sales: $8.6 billion, increasing 4.6%, with growth across cardiovascular, surgery, and vision segments.
• Free Cash Flow: Approximately $1.5 billion for Q1; full-year projection remains at $21 billion.
• Dividend: Authorized a 3.1% increase to an annual rate of $5.36 per share, marking the 64th consecutive year of dividend growth.

2. Strategic Updates and Business Highlights

• Innovative Medicine: Strong performance driven by key brands like DARZALEX (sales of $4 billion, 18% growth) and TREMFYA (64% growth). New product launches such as ICOTYDE and INLEXZO are expected to enhance growth.
• MedTech: Continued investment in high-growth areas, with notable advancements in electrophysiology and surgical robotics (OTTAVA system).
• Pipeline Strength: 28 products generating over $1 billion in annual revenue; ongoing FDA approvals and breakthrough designations for several therapies.
• Acquisitions: Positive impact from the Intra-Cellular acquisition, contributing to sales growth and portfolio diversification.

3. Forward Guidance and Outlook

• 2026 Sales Guidance: Increased operational sales guidance to 5.9% - 6.9%, with a midpoint of $100.2 billion.
• Adjusted EPS Guidance: Raised by $0.02 to a range of $11.30 to $11.50, indicating a 5.7% growth at the midpoint.
• Long-term Growth: Confidence in achieving double-digit growth by the end of the decade, driven by new product launches and operational efficiencies.

4. Bad News, Challenges, or Points of Concern

• STELARA Decline: Experienced a significant 61.7% decline due to biosimilar competition, impacting overall growth metrics.
• R&D and Operating Margins: Innovative Medicine margin decreased from 42.5% to 39.7%, and MedTech margin fell from 25.9% to 22.3%, reflecting increased investments in new launches.
• Market Pressures: Competitive pressures in the MedTech space, particularly in surgical vision, and potential impacts from volume-based procurement in China.
• Interest and Other Income: Shifted to a net expense of $43 million compared to $128 million income in Q1 2025, indicating a less favorable financial environment.

5. Notable Q&A Insights

• ICOTYDE Launch: Early uptake shows 1,500 prescriptions written, with strong enthusiasm from physicians and patients. Positioned as a first-line systemic therapy for psoriasis.
• MedTech Market Sentiment: Despite some procedural softness early in Q1, management remains confident in robust underlying demand and growth catalysts.
• Competitive Landscape: Assurance from leadership on maintaining market leadership in cardiovascular and IVL markets despite emerging competition.
• INLEXZO Performance: Following J-code approval, there was a 90% increase in new patient insertions, indicating strong market reception and growth potential.

Overall, Johnson & Johnson's Q1 2026 results reflect a strong start to the year, with significant growth in innovative medicine and a strategic focus on high-potential areas, despite facing challenges from competitive pressures and declining metrics in certain segments. The company remains optimistic about its long-term growth trajectory and pipeline strength.